Structural aspects of the p53 protein in relation to gene evolution: a second look.

Several years ago, a comparison of the amino acid sequences of p53 proteins from a variety of species enabled us to reveal structural features of this protein, giving clues to its function. Since then, numerous studies on the biochemical, immunological and biological functions of p53 as well as on its structure (including crystallography data) have provided considerable insight into the multifunctional aspects of p53. The purpose of this review is to present the most recent data concerning the various structural features of the p53 protein with special emphasis on its flexibility, which plays a key role in regulation of its biological activity.

[1]  P. Shaw,et al.  Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. , 1996, Oncogene.

[2]  A Estreicher,et al.  The human tumour suppressor gene p53 is alternatively spliced in normal cells. , 1996, Oncogene.

[3]  D. Smith,et al.  p53 point mutation and survival in colorectal cancer patients. , 1995, Cancer research.

[4]  A. Fornace,et al.  Does the p53 Up-Regulated Gadd45 Protein Have a Role in Excision Repair? , 1995, Science.

[5]  R. Elledge,et al.  Life and death by P53 , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[6]  D. Lane,et al.  Small peptides activate the latent sequence-specific DNA binding function of p53 , 1995, Cell.

[7]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[8]  P. Tegtmeyer,et al.  The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[10]  V. Rotter,et al.  Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)n repeats. , 1995, Oncogene.

[11]  D. Lane,et al.  Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner (*) , 1995, Journal of Biological Chemistry.

[12]  P. Tegtmeyer,et al.  Role of cysteine residues in regulation of p53 function , 1995, Molecular and cellular biology.

[13]  A. Levine,et al.  p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches , 1995, Cell.

[14]  C. Prives,et al.  Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus , 1995, Cell.

[15]  B. Madewell,et al.  Sequence analysis of canine p53 in the region of exons 3-8. , 1995, Cancer letters.

[16]  A. Levine,et al.  The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Harris,et al.  Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. , 1995, Oncogene.

[18]  D. Lane,et al.  Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  J. Milner,et al.  p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. , 1995, Oncogene.

[20]  S. Friend,et al.  Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. , 1995, Oncogene.

[21]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[22]  A M Gronenborn,et al.  Interhelical angles in the solution structure of the oligomerization domain of p53: correction , 1995, Science.

[23]  J Milner,et al.  Flexibility: the key to p53 function? , 1995, Trends in biochemical sciences.

[24]  T. Halazonetis,et al.  The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. , 1995, The EMBO journal.

[25]  J. Kovarik,et al.  Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. , 1995, Oncogene.

[26]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[27]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[28]  A. Levine,et al.  Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression , 1995, Molecular and cellular biology.

[29]  C. Arrowsmith,et al.  Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.

[30]  K. Vousden,et al.  Transcriptional activation by p53 correlates with suppression of growth but not transformation , 1994, Cell.

[31]  A. Meyer,et al.  Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. , 1994, Oncogene.

[32]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[33]  A. Albor,et al.  Cloning of the syrian hamster p53 gene: Structural and functional characterization of the upstream promoter region , 1994, Molecular carcinogenesis.

[34]  M. Rivkina,et al.  State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. , 1994, Cancer research.

[35]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[36]  D. Lane,et al.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. , 1994, Oncogene.

[37]  T. Crook,et al.  Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. , 1994, Oncogene.

[38]  A. Hasegawa,et al.  Cloning of feline p53 tumor‐suppressor gene and its aberration in hematopoietic tumors , 1994, International journal of cancer.

[39]  T. Soussi,et al.  Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. , 1994, The EMBO journal.

[40]  J. E. Stenger,et al.  p53 domains: structure, oligomerization, and transformation , 1994, Molecular and cellular biology.

[41]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[42]  A. Gronenborn,et al.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.

[43]  T. Soussi,et al.  Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. , 1994, Oncogene.

[44]  J. Milner.  Forms and functions of p53. , 1994, Seminars in cancer biology.

[45]  J. Shay,et al.  A temperature‐sensitive mutant of human p53. , 1994, The EMBO journal.

[46]  D. Meek.  Post-translational modification of p53. , 1994, Seminars in cancer biology.

[47]  D. Lane,et al.  Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. , 1994, Cancer research.

[48]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[49]  T. Soussi,et al.  Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. , 1994, British Journal of Cancer.

[50]  T. Soussi,et al.  Multifactorial analysis of p53 alteration in human cancer: A review , 1994, International journal of cancer.

[51]  D. Meek,et al.  Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. , 1994, The Journal of biological chemistry.

[52]  K. Kinzler,et al.  Sequence-specific transcriptional activation is essential for growth suppression by p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Harris,et al.  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Kulesz-Martin,et al.  Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells , 1994, Molecular and cellular biology.

[55]  G. Wu,et al.  Sequence of a cDNA encoding the p53 protein in rhesus monkey (Macaca mulatta). , 1994, Gene.

[56]  M. Williamson,et al.  The structure and function of proline-rich regions in proteins. , 1994, The Biochemical journal.

[57]  P. Laurent-Puig,et al.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.

[58]  J. E. Stenger,et al.  p53 domains: identification and characterization of two autonomous DNA-binding regions. , 1993, Genes & development.

[59]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[60]  X. Chen,et al.  A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.

[61]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[62]  P. Hainaut,et al.  Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. , 1993, Cancer research.

[63]  E. Winchester,et al.  Inhibition of DNA replication factor RPA by p53 , 1993, Nature.

[64]  D. Lane,et al.  Activation of the cryptic DNA binding function of mutant forms of p53. , 1993, Nucleic acids research.

[65]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[66]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[67]  M. Fiscella,et al.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Subler,et al.  p53 binds to the TATA-binding protein-TATA complex. , 1993, The Journal of biological chemistry.

[69]  M. Fiscella,et al.  Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. , 1993, Oncogene.

[70]  C. Miller,et al.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription , 1993, Molecular and cellular biology.

[71]  M. Zhu,et al.  Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. , 1993, Oncogene.

[72]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[73]  J Milner,et al.  A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. , 1993, Cancer research.

[74]  T. Halazonetis,et al.  Wild‐type p53 adopts a ‘mutant’‐like conformation when bound to DNA. , 1993, The EMBO journal.

[75]  R. Schneider,et al.  Structure of the rat p53 tumor suppressor gene. , 1993, Nucleic acids research.

[76]  C. Ingles,et al.  Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. , 1993, The Journal of biological chemistry.

[77]  T. Soussi,et al.  Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. , 1993, Bulletin du cancer.

[78]  G. Zambetti,et al.  Wild-type p53 binds to the TATA-binding protein and represses transcription. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[79]  K. Ogawa,et al.  Alternatively-spliced p53 mRNA in the FAA-HTC1 rat hepatoma cell line without the splice site mutations. , 1992, Cell structure and function.

[80]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[81]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[82]  D. Lane,et al.  The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. , 1992, Cancer research.

[83]  K. Sakaguchi,et al.  Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53 , 1992, Molecular and cellular biology.

[84]  E. Appella,et al.  Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. , 1992, Oncogene.

[85]  D. Meek,et al.  Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. , 1992, Oncogene.

[86]  D. Lane,et al.  Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. , 1992, Journal of molecular biology.

[87]  W Eckhart,et al.  Phosphorylation sites in the amino-terminal region of mouse p53. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Hulla.  The rat genome contains a p53 pseudogene: detection of a processed pseudogene using PCR. , 1992, PCR methods and applications.

[89]  K. Lam,et al.  hsp70 binds specifically to a peptide derived from the highly conserved domain (I) region of p53. , 1992, Biochemical and biophysical research communications.

[90]  D. Beach,et al.  Human p53 inhibits growth in Schizosaccharomyces pombe , 1992, Molecular and cellular biology.

[91]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[92]  T. Soussi,et al.  The cDNA cloning and immunological characterization of hamster p53. , 1992, Gene.

[93]  T. Soussi,et al.  Rainbow trout p53: cDNA cloning and biochemical characterization. , 1992, Gene.

[94]  R. Sikorski,et al.  Human p53 and CDC2Hs genes combine to inhibit the proliferation of Saccharomyces cerevisiae , 1992, Molecular and cellular biology.

[95]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[96]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[97]  V. Rotter,et al.  A DNA binding domain is contained in the C-terminus of wild type p53 protein. , 1991, Nucleic acids research.

[98]  G. Lozano,et al.  An intron binding protein is required for transformation ability of p53. , 1991, Nucleic acids research.

[99]  P. Wagner,et al.  A human tumour-derived mutant p53 protein induces a p34cdc2 reversible growth arrest in fission yeast. , 1991, Oncogene.

[100]  J. Milner.  A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer , 1991, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[101]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[102]  M. Montenarh,et al.  Association of casein kinase II with immunopurified p53. , 1991, Oncogene.

[103]  R. Carroll,et al.  The tumor suppressor p53 is bound to RNA by a stable covalent linkage , 1991, Molecular and cellular biology.

[104]  A. Levine,et al.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. , 1991, Genes & development.

[105]  A. Levine,et al.  Tissue‐specific expression of p53 in transgenic mice is regulated by intron sequences , 1991, Molecular carcinogenesis.

[106]  J. Milner,et al.  Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. , 1990, Journal of molecular biology.

[107]  V. Rotter,et al.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis , 1990, Molecular and cellular biology.

[108]  A. Berk,et al.  Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. , 1990, Virology.

[109]  D. Meek,et al.  The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. , 1990, The EMBO journal.

[110]  J. Milner,et al.  p53 is associated with p34cdc2 in transformed cells. , 1990, The EMBO journal.

[111]  S. Fields,et al.  Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.

[112]  G. Lozano,et al.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.

[113]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[114]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[115]  P. Friedman,et al.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[116]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[117]  J. Jenkins,et al.  The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. , 1990, Oncogene.

[118]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[119]  C. Dang,et al.  Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. , 1989, The Journal of biological chemistry.

[120]  W. Eckhart,et al.  Nucleotide sequence of a cDNA encoding the monkey cellular phosphoprotein p53. , 1989, Nucleic acids research.

[121]  J. Jenkins,et al.  Ability of p53 and the adenovirus E1b 58-kilodalton protein to form a complex is determined by p53 , 1989, Journal of virology.

[122]  A. Levine,et al.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation , 1989, Journal of virology.

[123]  P. May,et al.  Nucleotide sequence of a cDNA encoding the chicken p53 nuclear oncoprotein. , 1988, Nucleic acids research.

[124]  T. Soussi,et al.  Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. , 1988, Nucleic acids research.

[125]  J. Jenkins,et al.  Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen , 1988, Journal of virology.

[126]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[127]  T. Soussi,et al.  Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. , 1987, Oncogene.

[128]  K. Chandrasekaran,et al.  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B‐cell lymphoma , 1987, International journal of cancer.

[129]  Wolf,et al.  Immunologically distinct p53 molecules generated by alternative splicing , 1986, Molecular and cellular biology.

[130]  A. Levine,et al.  Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex , 1986, Journal of virology.

[131]  L. Crawford,et al.  Characterization of the human p53 gene , 1986, Molecular and cellular biology.

[132]  D. Helfman,et al.  Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53 , 1985, Molecular and cellular biology.

[133]  D. Pim,et al.  Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. , 1984, The EMBO journal.

[134]  D. Givol,et al.  Analysis of the gene coding for the murine cellular tumour antigen p53. , 1984, The EMBO journal.

[135]  J. Jenkins,et al.  Cloning and expression analysis of full length mouse cDNA sequences encoding the transformation associated protein p53. , 1984, Nucleic acids research.

[136]  J. Milner.  Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes , 1984, Nature.

[137]  D. Goeddel,et al.  The amino acid sequence of murine p53 determined from a c-DNA clone. , 1984, Virology.

[138]  D. Givol,et al.  A single gene and a pseudogene for the cellular tumour antigen p53 , 1983, Nature.

[139]  A. Levine,et al.  Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[140]  L. Crawford.  The 53,000-dalton cellular protein and its role in transformation. , 1983, International review of experimental pathology.

[141]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[142]  F. McCormick,et al.  Lymphocyte stimulation: concanavalin A induces the expression of a 53K protein. , 1980, Cell biology international reports.